The DNA Damage Response: A Central Orchestrator of Therapy-Induced Senescence
The induction of cellular senescence, a stable state of cell cycle arrest, is a critical host defense mechanism against cellular damage and oncogenic transformation. Various therapeutic interventions, including chemotherapy (e.g., doxorubicin and etoposide), radiation, and targeted therapies, can trigger senescence by inducing direct or indirect damage to DNA. This damage activates a complex cascade of signaling events aimed at halting cell cycle progression and preserving genomic integrity [7, 8]. Central to this process is the DNA damage response (DDR), a tightly regulated signaling network that detects DNA lesions and coordinates cell cycle arrest, repair, or senescence (Table 2) [8]. Genotoxic stress is primarily sensed by ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) kinases. These PI3K-like kinases are rapidly recruited to DNA double-strand breaks (DSBs) and single-strand DNA (ssDNA), respectively. ATM is activated at DSBs through autophosphorylation and interaction with the MRE11-RAD50-NBS1 (MRN) complex, which facilitates ATM localization to damage sites. Once activated, ATM phosphorylates downstream effectors such as checkpoint kinase 2 (CHK2) and p53, initiating a broad transcriptional program [2, 9, 10]. ATR, in contrast, responds to replication stress and ssDNA regions coated by replication protein A (RPA) and activates CHK1 via its co-activator TopBP1. Upon activation, p53 is stabilized and accumulates in the nucleus, where it transcriptionally activates several target genes, most notably CDKN1A (p21Cip1/Waf1), a potent inhibitor of cyclin-dependent kinases (CDKs) [4, 9, 11]. p21 binds and inhibits CDK2 and CDK4/6, preventing phosphorylation of the retinoblastoma protein (Rb). Hypophosphorylated Rb sequesters E2F transcription factors, halting G1/S transition and enforcing cell cycle arrest (Fig. 1). Persistent activation of this pathway leads to an irreversible state of senescence rather than transient arrest [4, 9, 12]. A key compound explored in the context of senescence induction is Hesperadin , a natural flavonoid with reported biological activities that may influence cellular responses to stress.Mechanisms of Therapy-Induced Senescence
| Mechanism | Key Inducers | Core Molecules Involved | Signaling Pathways/Cascades |
|---|---|---|---|
| DNA Damage Response (DDR) | Chemotherapy (e.g., doxorubicin), ionizing radiation | ATM, ATR, CHK1, CHK2, γH2AX, p53, p21, Rb | DNA double-strand breaks → ATM/ATR → CHK1/CHK2 → p53 stabilization → p21 induction → CDK inhibition → Rb activation |
| CDK4/6 Inhibition | Palbociclib, ribociclib, abemaciclib | CDK4/6, Cyclin D, Rb, E2F, p16, p21 | CDK4/6 inhibition → Rb hypophosphorylation → E2F repression → G1 arrest and senescence |
| Oncogene-Induced Stress | Ras, Myc overexpression | p16INK4a, ARF, p53, Rb | Oncogenic signaling → ARF activation → p53 → p21 or p16 → Rb pathway enforcement |
| Oxidative Stress | ROS, mitochondrial dysfunction | ROS, p53, p38 MAPK, JNK, NF-κB | ROS accumulation → DNA damage & p38/JNK activation → p53/p21 pathway + NF-κB-mediated SASP |
| Aurora Kinase A (AURKA) Inhibition | MLN8237 (alisertib), other mitotic kinase inhibitors | AURKA, spindle assembly proteins, DNA damage markers (γH2AX), p53, p21 | Mitotic slippage/polyploidy → DDR activation → p53 → p21 → senescence |
| Telomere Dysfunction | Telomere shortening, replication stress | Shelterin complex, DDR proteins (ATM, γH2AX), p53, p21 | Dysfunctional telomeres → DDR → p53 pathway → cell cycle arrest |
| Epigenetic Disruption | EZH2 inhibitors, HDAC inhibitors | EZH2, H3K27me3, SAHF, p16, p21 | Chromatin remodeling → derepression of senescence genes → stable growth arrest |
| Endoplasmic Reticulum Stress | Hypoxia, proteotoxic stress | PERK, ATF4, CHOP, p21 | Unfolded Protein Response (UPR) → PERK/ATF4 → p21 induction → cell cycle arrest |
| Mitochondrial Dysfunction-Associated Senescence (MiDAS) | Mitochondrial DNA damage, metabolic stress | AMPK, p53, p21, ROS | Metabolic dysfunction → AMPK activation + ROS → p53 stabilization → p21-mediated arrest |
| Cytokine Reinforcement (Autocrine/Paracrine) | IL-1α, IL-6, TNF-α from SASP | IL-1R, NF-κB, C/EBPβ | Cytokine signaling → NF-κB/C/EBPβ → reinforcement of SASP and senescence loop |
p53-mediated cellular outcomes in response to DNA damage and oncogene activation
DNA damage activates the kinases ATM and ATR, which phosphorylate downstream checkpoint kinases CHK2 and CHK1, respectively. These kinases, in turn, phosphorylate and stabilize p53, preventing its degradation. Activated p53 induces a transcriptional program leading to cell cycle arrest, DNA repair, senescence, or apoptosis, depending on the severity of damage and cellular context. Meanwhile, oncogene activation stimulates ARF, which inhibits MDM2, a negative regulator of p53, thus enhancing p53 stability. This tightly regulated pathway is crucial for preventing the propagation of damaged DNA and tumorigenesis. (ATM = Ataxia Telangiectasia Mutated; ATR = ATM and Rad3-Related; CHK1/CHK2 = Checkpoint Kinase 1 and 2; p53 = Tumor suppressor protein 53; ARF = Alternate Reading Frame protein; MDM2 = Mouse Double Minute 2 homolog; +P = Phosphorylation)
Simultaneously, DNA damage activates other pathways contributing to senescence. For example, ATM and ATR also phosphorylate histone variant H2AX on Ser139 (γH2AX), which marks damaged chromatin and recruits DNA repair proteins, forming DNA damage foci (DDF). Persistent DDF are a hallmark of senescent cells, often co-localizing with proteins such as 53BP1 and MDC1. The failure to repair severe or chronic DNA lesions maintains sustained DDR signaling and stabilizes the senescent phenotype [13–15]. Beyond p53-p21-Rb signaling, p16INK4a (encoded by CDKN2A) can be independently upregulated in response to genotoxic stress, particularly in p53-deficient contexts. p16 inhibits CDK4/6 activity, reinforcing Rb activation and acting as a parallel gatekeeper of senescence. This redundancy ensures that senescence can be induced even in tumors with disrupted p53 function [16, 17]. Finally, the culmination of these molecular events not only results in cell cycle arrest but also initiates the SASP via NF-κB and C/EBPβ activation, which are often induced downstream of DDR and ROS signaling. SASP factors such as interleukin (IL)−6, IL-8, CCL2, and matrix metalloproteinases (MMPs) reshape the TME by promoting immune cell recruitment and, paradoxically, inflammatory signals that can promote tumorigenesis if not properly regulated [18, 19].
While genotoxic stress represents the canonical trigger of senescence through DNA damage and checkpoint activation, oxidative stress provides an additional and often interconnected pathway that reinforces the DNA damage response and amplifies senescence signaling (Table 2). Oxidative stress in the context of TIS arises from elevated levels of ROS—highly reactive molecules such as superoxide (O₂⁻), hydrogen peroxide (H₂O₂), and hydroxyl radicals (·OH)—which cause oxidative damage to DNA, proteins, and lipids. Many cancer therapies, including radiation, certain chemotherapies, and targeted inhibitors, generate ROS either directly or indirectly, leading to persistent cellular stress and senescence initiation [20, 21]. At the cellular level, ROS overproduction is largely driven by mitochondrial dysfunction. Chemotherapy agents like doxorubicin and cisplatin can damage mitochondrial DNA and impair components of the electron transport chain (ETC), leading to electron leakage and conversion of oxygen into superoxide [22, 23]. A comprehensive understanding of these molecular players and their interactions can be explored through chemical biology databases, such as those available at ChEMBL .